Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

[1]  T. Therneau,et al.  Assessing calibration of prognostic risk scores , 2016, Statistical methods in medical research.

[2]  G. Pond,et al.  Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. , 2016, Clinical genitourinary cancer.

[3]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[4]  J. Lunceford,et al.  Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. , 2015 .

[5]  D. Bajorin,et al.  First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients. , 2015, Hematology/oncology clinics of North America.

[6]  T. Choueiri,et al.  Future directions and targeted therapies in bladder cancer. , 2015, Hematology/oncology clinics of North America.

[7]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[8]  M. Jinzaki,et al.  The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. , 2014, Urologic oncology.

[9]  G. Pond,et al.  Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. , 2014, Urologic oncology.

[10]  G. Sonpavde,et al.  Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy , 2013, Cancer.

[11]  I. Ostrovnaya,et al.  Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. , 2013, Journal of the National Cancer Institute.

[12]  G. Sonpavde,et al.  Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. , 2012, Clinical genitourinary cancer.

[13]  M. Kattan,et al.  How to tell if a new marker improves prediction. , 2011, European urology.

[14]  G. Sonpavde,et al.  Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Sonpavde,et al.  First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  Eric R. Ziegel,et al.  The Elements of Statistical Learning , 2003, Technometrics.

[18]  M. Schemper,et al.  Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.

[19]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[21]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .